Eli Lilly and Company

Imclone LLC

Elanco US Inc.

Juqun Shen

Dale Lincoln Ludwig

Stephen John Demarest

Yang Shen

Zhenping Zhu

Yiwen Li

Vera Molkenthin

Yiqing Feng

Stephanie Marie Truhlar

Haijun Sun

James Robert Tonra

Douglas Bryan Burtrum

Cheng Wang

Marshall Davenport Snavely

The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.

Bispecific antibodies targeting immune checkpoints

The present disclosure relates to anti-canine platelet derived growth factor receptor alpha antibodies binding to canine platelet derived growth factor receptor alpha.

Anti-canine platelet derived growth factor receptor alpha antibody

The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.

PD-L1 antibodies

The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.

Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof

The invention is directed to novel PDGFR&#x3b2;-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFR&#x3b2;-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.

PDGFR&#x3b2;-specific antibodies

Growing community of inventors

Flushing, NY, United States of America

Juqun Shen